Trial · NCT01415752
Adverse events1,168
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 1,168
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anemia | Blood and lymphatic system disorders | Induction: Bendamustine + Rituximab (Arm A) | 61 | 93 | |
| other | Anemia | Blood and lymphatic system disorders | Induction: Bendamustine + Rituximab + Bortezomib (Arm B) | 54 | 92 | |
| other | Anemia | Blood and lymphatic system disorders | Induction: Bendamustine + Rituximab (Arm C) | 61 | 93 | |
| other | Anemia | Blood and lymphatic system disorders | Induction: Bendamustine + Rituximab + Bortezomib (Arm D) | 57 | 92 | |
| other | Anemia | Blood and lymphatic system disorders | Maintenance: Rituximab (Arm E) | 40 | 74 | |
| other | Anemia | Blood and lymphatic system disorders | Maintenance: Rituximab (Arm F) | 37 | 68 | |
| other | Anemia | Blood and lymphatic system disorders | Maintenance: Lenalidomide + Rituximab (Arm G) | 53 | 73 | |
| other | Anemia | Blood and lymphatic system disorders | Maintenance: Lenalidomide + Rituximab (Arm H) | 57 | 73 | |
| other | Edema limbs | General disorders | Induction: Bendamustine + Rituximab (Arm A) | 11 | 93 | |
| other | Edema limbs | General disorders | Induction: Bendamustine + Rituximab + Bortezomib (Arm B) | 14 | 92 | |
| other | Edema limbs | General disorders | Induction: Bendamustine + Rituximab (Arm C) | 15 | 93 | |
| other | Edema limbs | General disorders | Induction: Bendamustine + Rituximab + Bortezomib (Arm D) | 14 | 92 | |
| other | Edema limbs | General disorders | Maintenance: Rituximab (Arm E) | 5 | 74 | |
| other | Edema limbs | General disorders | Maintenance: Rituximab (Arm F) | 10 | 68 | |
| other | Edema limbs | General disorders | Maintenance: Lenalidomide + Rituximab (Arm G) | 11 | 73 | |
| other | Edema limbs | General disorders | Maintenance: Lenalidomide + Rituximab (Arm H) | 12 | 73 | |
| other | Fatigue | General disorders | Induction: Bendamustine + Rituximab (Arm A) | 67 | 93 | |
| other | Fatigue | General disorders | Induction: Bendamustine + Rituximab + Bortezomib (Arm B) | 63 | 92 | |
| other | Fatigue | General disorders | Induction: Bendamustine + Rituximab (Arm C) | 70 | 93 | |
| other | Fatigue | General disorders | Induction: Bendamustine + Rituximab + Bortezomib (Arm D) | 72 | 92 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01415752/events